Please login to the form below

Not currently logged in
Email:
Password:

Merck appoints new senior vice president

Laszlo Radvanyi joinsthe firm
Merck KGgA

Merck KGgA has appointed Laszlo Radvanyi as senior vice president and head of research in immuno-oncology.

Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the aim to deliver personalized treatments for patients.

Before joining Merck KGgA, Radvanyi served as chief scientific officer at Lion Biotechnologies based in Florida where he was responsible for developing new technologies to product next-generation TILs for tumor indications including lung, cervical and breast cancer.

Luciano Rossetti, head of global research and development, said: “We are honoured to have Laszio join Merck KGaA. His vast experience across the field of immuno-oncology research is very impressive.

“His expertise and fresh perspective will add significant value to our early-stage immuno-oncology portfolio including combination and biomarker strategies for avelumab and other clinical candidates, as we endeavour to bring new therapeutic options to patients living with cancer.”

4th November 2015

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...

Latest intelligence

The challenges of identifying rare diseases
With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...